Drugs / FIPRAVIRIMAT
FIPRAVIRIMAT
also known as
GSK3640254 · GSK'254 · [14C]-GSK3640254 · FIPRAVIRIMAT MESYLATE · GSK-3640254A · GSK-3640254D · GSK3640254 mesylate · GSK3640254/DTG
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT04857892 | Apr → Sep 2021 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04425902 | Dec 2020 → Mar 2021 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04563845 | Nov 2020 → Oct 2021 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04630002 | Oct 2020 → Oct 2021 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04507321 | Sep → Nov 2020 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04263142 | Jan → Mar 2020 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04128293 | Oct → Nov 2019 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 1 | NCT03984825 | Jun → Aug 2019 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT03836729 | Feb → Mar 2019 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT03816696 | Jan → Mar 2019 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT03575962 | Jun → Aug 2018 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT03231943 | Sep 2017 → Sep 2018 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04900038 | Aug 2021 → Nov 2022 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04493216 | Nov 2020 → Sep 2022 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03784079 | Jan 2019 → Feb 2020 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-02-28 | GlaxoSmithKline | Results ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV gsk.com ↗
Next-generation maturation inhibitor GSK3640254 showed broad spectrum potency without MI resistance |
| 2021-03-09 | GlaxoSmithKline | Results ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV gsk.com ↗
The study showed the antiviral activity of GSK’254, establishing a relationship between dose and antiviral response, with the 140 mg and 200 mg doses showing the greatest reduction in plasma HIV-1 RNA. |
| 2021-03-09 | ViiV Healthcare | Results ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV viivhealthcare.com ↗
The study showed the antiviral activity of GSK’254, establishing a relationship between dose and antiviral response, with the 140 mg and 200 mg doses showing the greatest reduction in plasma HIV-1 RNA. |
All press releases naming this drug 3 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FIPRAVIRIMAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5201510 ↗ |
| Known as | [14C]-GSK3640254 | “\[14C\]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.” NCT04507321 ↗ |
| Known as | FIPRAVIRIMAT MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5201510 ↗ |
| Known as | GSK'254 | “The DYNAMIC study evaluated the efficacy and safety of the maturation inhibitor GSK3640254 (GSK'254) plus dolutegravir (DTG) in adults naive to antiretroviral therapy.” PMID 41357331 ↗ Oct 20252“GSK3640254 (GSK'254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily therapy.” PMID 34996113 ↗ Sep 2022 “GSK3640254 (GSK'254) is a novel HIV-1 maturation inhibitor” PMID 37961928 ↗ Dec 2023 |
| Known as | GSK-3640254A | ChEMBL registry synonym — accepted as the source's own label CHEMBL5201510 ↗ |
| Known as | GSK-3640254D | ChEMBL registry synonym — accepted as the source's own label CHEMBL5201510 ↗ |
| Known as | GSK3640254 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04493216 ↗ |
| Known as | GSK3640254 mesylate | “This is an open-label, single-dose, four-period, four sequential, and crossover study conducted to assess the relative bioavailability of GSK3640254 mesylate tablets and...” NCT04128293 ↗ |
| Known as | GSK3640254/DTG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04857892 ↗ |
| Action | Inhibit | “GSK3640254 is a next-generation maturation inhibitor” PMID 34995417 ↗ Jan 2022 |
| Modality | Small molecule | — CHEMBL5201510 ↗ |
| Route | Oral | “GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.” NCT03231943 ↗ |